The step from drug discovery to clinical development is one of the most challenging hurdles, but also one of the most value gaining transformation of a potential drug.... → read more

December 1-2, 2021

Join us live to discuss the specific challenges associated with the synthesis and manufacture of Highly Potent Active Pharmaceutical Ingredients (HPAPIs)... → read more

November 23, 2021

The life science and pharma industry is in a transformative phase where targets formerly considered un-druggable are now the focus of well-funded biotech companies.... → read more

September 29-30, 2021

How to translate your oncology target into a preclinical candidate (PART 2)... → read more

September 16, 2021

Join live Dr. Martin Lange and Dr. Carlo Stresemann on a short journey into the oncology and translational research services at NUVISAN-ICB.... → read more

June 17, 2021

Administration of large molecules can trigger an immune response in patients, leading to the production of anti-drug-antibodies (ADA).... → read more

April 20, 2021

High throughput Screening (HTS) is a key element of the early drug discovery process and essential for the identification of molecules with suitable target-specific properties to develop a promising drug.... → read more

March 30, 2021

Biomarkers are measurable characteristics of a living organism, from blood pressure to the abundance of proteins or small molecule metabolites.... → read more

February 11, 2021

The pharmaceutical industry is often seen as an expensive activity that requires considerable R&D investments with no guaranties of return.... → read more

December 03, 2020

Most topical formulations developed today are complex and require tight control to be chemically and physically stable while meeting the targeted efficiency and delivering pleasant aesthetics.... → read more

October 20, 2020

The increasing complexity in the early development phase led to a booming demand for sophisticated CRO/CDMO partners.... → read more

July 28, 2020

Re-constitution of anti-tumor T cell responses by clinically approved immune checkpoint inhibitors (ICIs) represents a breakthrough cancer therapy.... → read more

March 01, 2022

The induction of relevant drug metabolizing enzymes such as... → read more

March 31, 2022

Converting a scientific hypothesis into a... → read more

June 23, 2022

After preclinical animal models and early safety testing, your investigational compound is ready for the First-in-Man (FIM) clinical safety trial in humans with the perspective of demonstrating proof-of-concept at an early stage using suitable surrogate markers depending on the mechanism of action.... → read more

September 29, 2022

The application of multiple biophysical techniques to validate initial HTS hits has become an important part of lead discovery.... → read more

October 20, 2022

How to Optimize your Clinical Drug supply: Tailored Solutions for Clinical Success... → read more

January 31, 2023

Balancing sustainability challenges versus scientific advancement and innovation in the Pharma Industry... → read more

November 1-10, 2022